Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation transactions should be finished after this ..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(198)
•••
Comment by Pragmatiston Jun 06, 2021 7:42pm
269 Views
Post# 33338143

RE:RE:RE:RE:RE:Amalgamation transactions should be finished after this ..

RE:RE:RE:RE:RE:Amalgamation transactions should be finished after this ..
Pragmatist wrote:
CalgaryATE wrote: Could it be as simple as selling to save enough to pay the taxman? I know they went with a three cornered amalgamation to reduce their taxes, but they probably still owe some. I imagine it wouldn't be fun trying to pay their taxes next April if they were in the middle of a lock up period (negotiating a buyout/partnership, middle of phase 3).
Doccole wrote:

I assumed there was selling from insiders.  The Canadian volume was high...


Insider selling tells me there is nothing on the horizon, or why would insider sell? Am I wrong? Please tell me I am?!


 
As long as they received nothing but Antibe shares as "consideration" for the amalgamation, they can defer capital capital gains on the Holdings shares.



Calgary...Pls disregard my last comment.  I see now you were referring to the initial share transfer which occured a few months back.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities